Abstracts tagged "quality improvement"

Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Francine Castillo¹, Michael Dodge ¹, Jung Hee Noh ², Laura Trupin ¹, Jinoos Yazdany ³ and Sarah Goglin ³, ¹University of California, San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 319 • 2019 ACR/ARP Annual Meeting
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Milena Gianfrancesco¹, Sara Murray ¹, Michael Evans ², Gabriela Schmajuk ³ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although generally well tolerated, the long-term use of hydroxychloroquine (HCQ) may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Kelly Corbitt ¹, Isis Lopez² and David Dillon ³, ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²University of Miami/ Jackson Memorial Hospital, Miami, FL, ³University of Miami/Jackson Memorial Hospital, Miami
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…
Abstract Number: 1126 • 2019 ACR/ARP Annual Meeting
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Sarah French¹, Joshua Ng ¹, Darlene Young ², Michael Evans ³, Tobias Schmelzinger ¹, Gabriela Schmajuk ⁴, Jinoos Yazdany ⁵ and Andrew Gross ¹, ¹UCSF, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁵UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing osteoporosis as compared to the general population, even after controlling for glucocorticoid use[1]. Identification…
Abstract Number: 1136 • 2019 ACR/ARP Annual Meeting
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Richard Zamore¹, ¹Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: No shows are a widespread problem across medical practices, and lead to negative consequences for patients and providers (Mendel 2017). The rheumatology division at…
Abstract Number: 1190 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project to Increase Documentation Efficiency in an Academic Rheumatology Practice
David Leverenz¹, Jon Golenbiewski ¹, Brian Andonian ¹, Katherine Kaufman ¹, Philip Chu ¹, Mithunan Maheswaranathan ¹, Andrew Johannemann ¹, Jayanth Doss ² and Lisa Criscione-Schreiber ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: All providers, including rheumatologists, spend approximately half of their day documenting in an electronic health record (EHR). Excessive documentation is a key contributor to…
Abstract Number: 1192 • 2019 ACR/ARP Annual Meeting
Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital
Hiroki Ozawa¹, Sho Fukui ¹, Genki Kidoguchi ¹, Takehiro Nakai ², Satoshi Kawaai ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a common, preventable and treatable complication of glucocorticoid therapy. We defined quality indicator (QI) for GIOP and took a hospital-wide…
Abstract Number: 1202 • 2019 ACR/ARP Annual Meeting
Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies
Claire Barber¹, Dianne Mosher ², Glen Hazlewood ¹, Paul MacMullan ², Cheryl Barnabe ², Victoria Bohm ², James Rankin ², Joanne Homik ³, Kelly English ⁴, Karen Tsui ⁵, Bo Pan ⁶, Martina Stevenson ², Namneet Sandhu ², Andrea Emrick ², Liam Martin ¹, Caylib Durand ², Michelle Jung ² and Diane Lacaille ⁷, ¹University of Calgary, Calgary, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Alberta, Edmonton, Canada, ⁴Arthritis Patient Advocacy Board, Vancouver, BC, Canada, ⁵Arthritis Patient Advisory Board, Toronto, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The purpose of this study was to operationalize and report on 3 Rheumatoid Arthritis (RA) performance measures previously identified in the Patient-Centered Framework for…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…
Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Shakaib Hayat¹ and Stanley Ballou ², ¹Case Western Reserve University (MetroHealth), Cleveland, OH, ²Metrohealth medical center, Cleveland, OH
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].